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Homeobox 2Microarray proﬁling in breast cancer patients has identiﬁed genes correlated with prognosis whose functions
are unknown. The purpose of this studywas to develop an in vivo assay for functionally screening regulators of
tumor progression using a mouse model. Transductant shRNA cell lines were made in the MDA-MB-231
breast cancer line. A pooled population of 25 transductants was injected into the mammary fat pads and tail
veins of mice to evaluate tumor growth, and experimental metastasis. The proportions of transductants were
evaluated in the tumor and metastases using barcodes speciﬁc to each shRNA transductant. We characterized
the homeobox 2 transcription factor as a negative regulator, decreasing tumor growth in MDA-MB-231, T47D,
and MTLn3 mammary adenocarcinoma cell lines. Homeobox genes have been correlated with cancer patient
prognosis and tumorigenesis. Here we use a novel in vivo shRNA screen to identify a new role for a homeobox
gene in human mammary adenocarcinoma.egall).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.1. Introduction
Breast cancer is the most common malignancy and the second
most common cause of cancer related death in women. Ninety
percent of deaths from tumors are due to metastasis, making the
pathophysiology of this process and the study of genes involved in
regulating metastasis central to advancing our understanding of this
disease [1]. Oncogenes and tumor suppressor genes have been an
important focus of study and drug design, as both metastasis growth
and signiﬁcant tumor burden contribute to poor clinical outcome.
However individually evaluating these genes is time consuming.
Screens can expedite functional validation of many proposed
oncogenes and tumor suppressors in order to identify potential
drug candidates. Breast cancer microarray studies have attempted to
characterize the prognostic proﬁle and therapeutic sensitivities of
patients. Expression signatures predicting clinical outcome have
correlated microarray studies with breast cancer patient prognosis
[2–5]. The results of these studies, as well as those used in the clinical
setting, indicate that clinical microarray data may provide large
numbers of candidate genes to be evaluated for their contributions to
both tumor growth and metastasis [6,7].
Developing a high-throughput in vitro screen based on shRNA
lentiviral vectors has been previously demonstrated [8,9]. In those
studies, genes were down-regulated in cells using shRNAs in a pooledpopulation and placed under an in vitro outgrowth assay to select for
genes regulating in vitro tumor cell growth. Although in vitro studies
allow for rapid evaluation and selection of a large number of target
genes, they neglect the importance of the tumor microenvironment.
The screen we developed uses in vivo assays for breast cancer cell
growth in the primary tumor and seeding and growth of lung
metastases after tail vein injection to select for genes regulating these
processes. Similarly, an in vivo screen for tumor suppressors in liver
cancer used shRNA pools to identify and validate tumor suppressor
genes in a liver mousemodel [10]. Formation and growth of the tumor
as well as the metastatic cascade are complex processes involving
extensive input from the microenvironment and supporting stroma,
making in vivo studies imperative for functional characterization of
genes.
In this study we detected changes in the proportions of individual
cell lines within a pooled population compared to the original injected
pool proportions after selection for in vivo primary tumor growth in
the mammary fat pad or seeding and growth in the lungs after
experimental metastasis. We found that the HOXB2 transcription
factor acts as a negative tumor growth regulator, decreasing
proliferation in mammary adenocarcinoma tumors.2. Results
2.1. Experimental design
To develop this screen we chose to evaluate genes correlated with
patient prognosis across three breast cancer microarray analyses
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shRNA transductant cell lines using the breast cancer line MDA-MB-
231 clone 4173, previously identiﬁed as being highly metastatic to the
lungs [11]. Each shRNA transductant cell linewasmade separately as a
pool of transductants generated from a pGipz shRNA lentiviral vector
designed to downregulate expression of a selected gene. The pGipz
vector (from Open Biosystems) contains a CMV promoter driving
expression of GFP, a puromycin resistance gene, and an shRNA off a
single mRNA using an IRES sequence. Since the GFP and shRNA are
present on the same mRNA, GFP levels could be used to estimate
shRNA expression. The GFP levels of transductant pools with different
targeted genes were similar, indicating similar levels of shRNA
expression (Supplemental Fig. 1). Each vector contains a unique 60
base pair barcode sequence which was used to identify the integrated
vector and determine the proportion of the transductants carrying
that vector in the population in the screen. Knock-down of the
targeted gene in each of the 25 shRNA transductant cell lines was
evaluated by quantitative Real Time-PCR, qRT-PCR, of cDNA with
primer sets to each gene. Up to four shRNA vectors were evaluated for
knockdown of the targeted gene, and the shRNA cell lines with the
highest knockdown for each genewere selected (Supplemental Tables
1 and 2). Multiple shRNA cell lines per gene were included in the
screen if there was more than one shRNA with high knockdown. To
make the pooled population of shRNA transductants, equal numbers
of cells of each of the 25 shRNA transductant cell lines were combined.
In order to detect changes in the proportion of each individual shRNA
transductant in the pool, speciﬁc qRT-PCR primers to the unique 60
base pair barcode sequences in each of the 25 vectors were designed
and tested. A common forward primer was used to hybridize to the
vector DNA in between the shRNA and the barcode and a speciﬁc
reverse primer was designed for each of the individual unique 60 bp
barcodes (Supplemental Table 3). SYBR green qRT-PCR was done to
determine the initial proportion of each individual transductant's
DNA within the pool.Tumor growth Assay
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Fig. 1. Experimental design of screen. The pool of transductants was injected into the right
tumor growth regulators and into the tail vein of female SCID mice (Experimental Metastasi
and genomic DNA isolated at the same time point as the in vivo samples. For mammary fa
dissociated and plated in puromycin containingmedium to select for tumor cells. For tail vein
and tumor cells plated and plated in puromycin containing medium to select for tumor cells. T
from puromycin resistant cultures, and speciﬁc barcode primers were used to evaluate the c
the proportions in the initial injected pool sample.2.2. In vivo screen for regulators of tumor growth and metastasis
For the in vivo screen, the shRNA pool was either injected into the
mammary fat pads of female SCID mice to identify tumor growth
regulators or injected via tail vein to identify regulators of lung
seeding and growth (Fig. 1). Genomic DNA, gDNA, was isolated from
the pool for later comparison with the in vitro and in vivo grown
samples. The pool was also grown in vitro in parallel. After four weeks
the lungs were removed from the tail vein injected mice and at six
weeks the primary tumors were removed. The tumors and lungs were
dissociated, plated and tumor cells were selected using the puromycin
resistance present in the pGipz vector. The in vitro cultures grown in
parallel were similarly treated. gDNA was isolated and SYBR green
qRT-PCR done using the barcode speciﬁc primers to look at the change
in the relative proportion of each individual transductant within the
total pool. The average proportion of each of the individual
transductant cell lines within the pool after in vivo and in vitro
growth was compared to the initial pool proportions (Table 1, and
Fig. 2). If the proportion of a cell line increased in the pool after growth
in the primary tumor or lung metastases, then the gene targeted by
the corresponding shRNA potentially inhibits tumor growth and/or
metastasis. If the proportion of a cell line decreased in the pool after
growth in the primary tumor or lung metastases, then the targeted
gene potentially stimulates tumor growth and/or metastasis.
ANOVA analysis of the relative proportions of the individual
transductants before and after in vitro growth indicated a signiﬁcant
change (pb .031). Examining the individual transductants' propor-
tions after in vitro growth identiﬁed 7 genes (CBFB, COL4A5, CYBA,
ID1, MPHOSPH6, PTPN14, and SERPINE1) whose proportions in the
pool were signiﬁcantly reduced after in vitro growth (t test, pb .05).
ANOVA analysis of the in vivo samples showed more signiﬁcant
changes (pb10−19 and .0021, respectively, for primary tumor growth
and lung growth). For primary tumor growth, 12 transductants
showed proportions that were signiﬁcantly altered. TransductantsExperimental
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Table 1
Summary of screen results.
In vitro p Primary p Lung p
BAI2-B 0.68 4.10E−01 0.76 5.06E−01 0.60 1.38E−01
CBFB-B 0.52 1.65E−01 1.53 5.83E−01 0.32 1.31E−03
CBFB-C 0.32 2.60E−02 0.96 8.59E−01 0.39 1.70E−02
CEBPB-E 0.99 9.88E−01 0.69 2.88E−01 1.34 2.76E−01
CELSR2-A 0.94 7.89E−01 0.26 5.73E−04 1.26 5.61E−01
COL4a5-B 0.36 4.27E−02 0.31 2.36E−07 0.68 3.90E−01
CT1 1.86 2.30E−01 9.89 1.28E−02 1.08 8.70E−01
CYBA-B 0.33 1.78E−02 0.11 5.81E−08 0.93 7.13E−01
EGFR 0.78 5.26E−01 0.86 5.42E−01 2.14 3.12E−01
EREG 1.01 9.79E−01 0.35 2.41E−05 1.09 1.11E−01
HIF1A-D 1.31 4.23E−01 0.94 7.02E−01 1.82 6.08E−02
HOXB2-A 1.26 3.80E−01 6.75 1.93E−02 1.66 4.01E−01
ID1-C 0.24 1.74E−02 0.12 8.40E−09 0.68 3.78E−01
IGF1R-B 0.83 6.93E−01 1.56 1.91E−01 0.86 2.17E−01
IGF1R-D 0.90 3.87E−01 0.93 8.64E−01 0.53 1.72E−01
IL13RA2 0.49 6.87E−02 0.74 3.79E−01 1.42 1.40E−01
MPHOSPH6 0.20 1.36E−02 0.26 2.46E−05 1.35 4.56E−01
MTX2 1.26 3.19E−01 2.21 3.04E−01 0.75 8.47E−02
PTPN14-D 0.38 3.33E−02 1.34 1.91E−01 1.13 4.66E−01
RHOC 2.32 4.20E−01 0.67 1.82E−01 1.57 2.18E−02
RLN2-A 0.55 1.48E−01 0.82 7.01E−01 0.57 7.32E−02
SERPINE1-B 0.50 4.37E−02 0.59 1.54E−01 0.77 2.34E−01
STC2-C 0.87 6.76E−01 0.19 3.89E−07 0.62 2.09E−02
TGFBI-C 0.89 3.71E−01 0.39 1.30E−02 0.67 3.18E−03
VCAM1-B 0.77 5.89E−01 0.37 1.86E−02 0.74 5.82E−01
VCAM1-C 1.00 9.98E−01 0.30 3.39E−04 0.79 2.83E−01
Legend. Changes in proportion of each shRNA transductant cell line in the screen. Data
shown are average change in proportion compared to the initial transductant pool for
growth in vitro (N=3), primary tumor growth (N=9), and experimental lung
metastasis (N=3). p Values are t tests against a reference constant value of 1 (no
change in proportion). Items in bold type correspond to a p value of b.05.
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166 P.J. Boimel et al. / Genomics 98 (2011) 164–172whose proportions were altered in both the in vitro growth and
primary tumor were COL4A5, CYBA, ID1, and MPHOSPH6, (Fig. 3). Of
the transductants whose proportions were altered only in the primary
tumor, CELSR2, EREG, and VCAM1 (2 different shRNAs) showed
reduced proportions after growth in the primary tumor, while HOXB2
and the line expressing what is described by Open Biosystems as a
non-targeting shRNA (CT1) showed increased proportions. Trans-
ductants whose proportions were altered both in the primary tumor
and experimental lung metastases were STC2 and TGFBI (both
decreased), while the RHOC transductant showed a slight increase
in lung metastasis. Two independent CBFB shRNA transductants were
reduced both in the in vitro growth and lungs but not in the primary
tumor (Fig. 3).Fig. 2. In vivo screen for regulators of tumor growth and metastasis. Bars of potential
growth/metastasis enhancers are black, potential growth/metastasis suppressors are
white, controls (previously published positive enhancers of metastasis) are in a
diagonal stripe pattern, and the non-targeting shRNA CT-1 is in a horizontal stripe
pattern. (A) Average fold change of shRNA transductants after growth in the primary
tumor. Nine female SCID mice were injected in the mammary fat pad with 1×106 cells
of the initial pool. After 6 weeks tumors were removed, dissociated with collagenase,
hyaluronidase, and DNase I and plated under puromycin selection. Genomic DNA was
isolated from the cells and used to determine the average fold change in proportion to
the initial pool using qRT-PCR with speciﬁc barcode primer sets. Means and SEM of
results from primary tumors from 9mice are plotted. (B) Average fold change of shRNA
transductants after seeding and growth in lung metastases. 1×106 cells of the initial
pool were injected in PBS into the lateral tail vein of female SCID mice. After 4 weeks,
lungs were extracted and dissociated with collagenase, hyaluronidase, and DNase I and
metastases plated under puromycin selection. Genomic DNAwas isolated from the cells
and used to determine the average fold change in proportion to the initial pool using
qRT-PCR with speciﬁc barcode primer sets. Mean and SEM are plotted for results from 3
separate mice. (C) Average fold change to injected pool proportions after in vitro
growth. The initial pool was grown in vitro and split 1:5, 3 times per week over 6 weeks
(two separate 6 week in vitro growth measurements were done of the initial pool, over
the time period of the two separate in vivo tumor injections). Genomic DNA was
isolated at 4 and 6 weeks, and used to determine the average fold change in proportion
to the initial pool using qRT-PCR with speciﬁc barcode primer sets. The average was
taken of the fold change from the 4 week, and two 6 week isolations. Means and SEM of
the data are plotted.
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Fig. 3. Relationships between transductants with signiﬁcant changes in representation. For genes that were signiﬁcantly altered in the screen, the effect of knockdown on
transductant representation in the pool is indicated by arrows (down indicates reduced representation and up indicates increased representation). The genes are organized
according to the selection under which their representation is altered.
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Fig. 4. The CBFB shRNA cell line is not altered in lung metastasis. The MDA-MB-231
parental cell line, SERPINE1-A, and CBFB-C shRNA cell lines were evaluated for seeding
and growth in the lungs after tail vein injection. 2.5×105 cells were injected into the
lateral tail vein of female SCID mice for each cell line. After 3 weeks lungs were formalin
ﬁxed, sectioned and H&E stained, and the number of lung metastases was counted.
Mean and SEM are plotted for measurements from 5 mice for each cell line. There were
no signiﬁcant differences.
167P.J. Boimel et al. / Genomics 98 (2011) 164–172Of the potential positive effector targets, the inhibitor of DNA
binding (ID1) shRNA transductant decreased in all conditions, and
signiﬁcantly in the in vitro and primary tumor samples. The epiregulin
(EREG) shRNA transductant decreased signiﬁcantly only in the
primary tumor samples. For the vascular cell adhesion molecule,
(VCAM1), there were two different shRNA transductants and both
decreased signiﬁcantly in the primary tumor. The EGFR and RHOC
transductants did not show any signiﬁcant changes. The most
surprising result was the dramatic increase in the non-targeting
shRNA (CT1) line in primary tumor growth (Fig. 2A).
2.3. HOXB2 is a negative growth regulator
We then tested selected lines that were identiﬁed in the screen to
determine their individual in vivo growth properties, and proliferative
and invasive capacity in vitro. We had found that the non-targeting CT1
cell line increased in proportion in the tumor growth screen, indicating
that it had off-target effects.We therefore proceeded using SERPINE1-A,
which had no knockdown of its targeted gene (Supplemental Table 1),
as an alternative control. The CBFB-C shRNA cell line was tail vein
injected to evaluate if it would have decreased lung seeding and growth
compared to the parental line or the SERPINE1-A control cell line. There
was no signiﬁcant difference in the number of total lung metastases
between the parental, SERPINE1-A, or CBFB-C cell lines (Fig. 4). CBFB
knockdown also had no effect on in vitro invasion or proliferation
compared to the SERPINE1-A control line (Supplemental Figs. 2 and 3).
To evaluate genes indicated to regulate growth in the in vivo
primary tumor screen we injected shRNA cell lines individually into
the mammary fat pads of female SCID mice to measure tumor growth
curves. We tested the lines which had the most dramatic fold changecompared to the initial injected pool proportions as well as TGFBI,
which speciﬁcally decreased in proportion after in vivo tumor growth
and not after in vitro growth. Tumor growth for the CYBA and TGFBI
shRNA transductant cell lines, evaluated individually, indicated no
signiﬁcant difference in the number of days it took for the average
tumor volume to reach 1000 mm3 compared to either the MDA-MB-
Table 2
Tumor growth of individual pGipz cell lines.
Cell line Days to grow 1000 mm3 tumor Number of mice
MDA-MB-231 parental 47 (+/−3 days) 5
pGipz CT-1 35 (+/−2 days) (p=0.023658) 4
pGipz CYBA-B 48 (+/−2 days) 6
pGipz TGFBI-C 44 (+/−3 days) 3
pGipz SERPINE1-A
(alternate control)
44 (+/−3 days) 10
pGipz HOXB2-A 33 (+/−2 days) (p=0.001011) 9
Legend. 1×106 cells were injected into the mammary fat pads of female SCID mice.
Tumors were measured every 3 days for up to 58 days and the mean and SEM number
of days to reach a tumor volume of 1000 mm3were calculated. p Values for cell lines
whose tumor growth was signiﬁcantly different from the SERPINE1-A control shRNA
line are provided. Mean and SEM are shown for the given number of separate mouse
injections.
168 P.J. Boimel et al. / Genomics 98 (2011) 164–172231 parental or Serpine1-A control cell lines (Table 2). Similar to the
characterization of the individual cell line in vivo, knockdown of CYBA
had no effect on the in vitro proliferation or invasive capacity of this
cell line (Supplemental Figs. 2 and 3). The CT1 shRNA cell line tumors
grew at a signiﬁcantly accelerated rate compared to the other cell
lines, consistent with its increase in proportion in the screen after
tumor growth (Table 2).
The HOXB2 shRNA cell line tumors grew more rapidly, taking
33 days to reach an average tumor volume of 1000 mm3, consistent
with the increase in proportion in the screen after tumor growth
(Table 2, and Fig. 5A). Knockdown of HOXB2 in the T47D humanTumor growth for MDA-MB-231
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Fig. 5. HOXB2 negatively regulates tumor growth. (A) HOXB2-A shRNA cell line tumors grew
mammary fat pads of female SCID mice. Two separate injections of 5 and/or 4 mice were per
3 days for 45 days. Data represent the mean and SEM of 10 mice for the SERPINE1-A shRNA
p≤0.05 at the indicated time points. At 45 days, p≤0.000181. (B) HOXB2 has no effect on i
SERPINE1-A cell lines were seeded in 6 well dishes at 50,000 cells per well and cells were co
Relative growth was calculated as a ratio of the average cell number at each time point to th
triplicate and repeated three times. Data are mean and SEM. There were no signiﬁcant differ
the JP1520 vector control cell line. 1×106 cells were injected into the mammary fat pads of 1
were measured and volumes calculated in mm3 every 3 days for 45 days. Data represen
overexpression in MTLn3 rat adenocarcinoma cells decreased tumor growth. 5×105 cells we
were measured and volume was calculated over 30 days. Data shown are mean and SEM, smammary adenocarcinoma cell line also increased tumor growth
signiﬁcantly compared to the SERPINE1-A control (Supplemental
Fig. 4). This conﬁrmed the screen result that HOXB2 may be a tumor
growth suppressor and we further evaluated this possibility by
overexpressing the HOXB2 open-reading frame in the JP1520 vector
in both MDA-MB-231 and the rat mammary adenocarcinoma cell line
MTLn3-ErbB1 [12]. There was no signiﬁcant difference in in vitro
growth of the HOXB2 shRNA and ORF cell lines compared to controls
over 96 h (Fig. 5B). The tumors with HOXB2 overexpressed grew
signiﬁcantly slower than the empty vector control JP1520 cell line
(Fig. 5C and D), consistent with HOXB2 regulating growth speciﬁcally
in the tumor microenvironment.
There were an increased percentage of cells inmitosis in the HOXB2
shRNA tumors and decreased mitosis in the HOXB2 ORF tumors
compared to the empty vector controls (Fig. 6). Similar results were
seen for the MTLn3-HOXB2 overexpressors. We saw no difference in
apoptosis in the primary tumor as indicated by terminal deoxynucleo-
tidyl transferase mediated-dUTP nick end labeling (TUNEL) staining in
the tumor parenchyma (data not shown). We evaluated in vitro
proliferation with 7-Aminoactinomycin D (7AAD) cell cycle analysis
using MODFIT software (BrdUwas also done, data not shown) and saw
no signiﬁcant difference compared to the parental MDA-MB 231 and
SERPINE1-A control cell lines (Supplemental Fig. 2A and B). We saw no
difference in in vitro survival with HOXB2 knockdown as indicated by
annexin V staining (Supplemental Fig. 2C). We conclude that the
increase in tumor growth with HOXB2 knockdown, and decreased
growth with overexpression is attributable to changes in proliferation
that are revealed in the tumor microenvironment.Tu
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In this study we performed an in vivo shRNA screen and were able
to determine the changes in proportion of the knockdown cell lines
after selection for in vivo tumor growth as well as seeding and growth
in lung metastases after tail vein injection. The processes of tumor
growth and metastasis are very sensitive to the in vivo architecture
and microenvironment, making screens such as this important in
elucidating the in vivo speciﬁc roles of the particular proteins being
studied.
To correlate and validate the results of the in vivo screen we
evaluated individual cell lines whose proportions changed in the
pooled screen population. We prioritized genes for evaluation whose
proportion change coincided with our hypothesized prediction based
on its correlation with patient prognosis in breast cancer microarray
studies. We were able to identify representatives of two categories of
genes: genes which affect in vivo growth both in a mixture of cell lines
and individually (HOXB2), and geneswhich differentially affect in vivo
growth of tumor cells depending on whether the cells are in
competition with other tumor cells (CYBA).
Knockdown of HOXB2 in two different breast cancer cell lines
(MDA-MB-231 and T47D) resulted in increased primary tumor
growth. Conversely, overexpression of the HOXB2 ORF in MDA-MB-
231 and MTLn3-ErbB1 breast cancer lines reduced primary tumor
growth. However, the effects on in vitro growth properties were not
signiﬁcantly different from control, indicating an in vivo speciﬁc effect
that may be dependent on the tumor microenvironment. We did ﬁnd
a small but signiﬁcant increase in invasiveness of cells suppressed in
expression of HOXB2, and it is possible that the increased invasion
may contribute to the increased in vivo growth rate. HOXB2 is part of
the homeobox family of genes, which are important in normalvertebrate limb and organ development [13–16]. Overexpression of
various homeobox genes have been correlated with lung, ovarian,
cervical, and breast cancer progression [17–22]. However, HOX genes
can also function in a tumor suppressor role in prostate and bladder
cancer [23,24]. In breast cancer, the HOXA5 gene was shown to
regulate p53 transcription, with its methylation/silencing resulting in
down-regulation of p53 expression and subsequent p53 mediated
malignant transformation [25]. The HOX genes function in a delicate
balance, with either overexpression or downregulation causing
transformation depending on the speciﬁc HOX gene and tissue
speciﬁcity. Our results are particularly interesting in that they
demonstrate an in vivo function for HOXB2 that was not detectable
by in vitro assays.
Our results are at odds with previous HOXB2 studies in pancreatic,
lung, and cervical cancer where overexpression was associated with
malignancy [21,22,26]. However, breast cancer data in the Oncomine
[27] and KMPlot [28] databases support our analysis. Overexpression
of HOXB2 was correlated with a better prognostic outcome: Kaplan
Meier plots from breast cancer patients indicate that overexpression
of HOXB2 correlates with longer relapse free survival. HOXB2
expression was signiﬁcantly increased (pb .05) in estrogen receptor
positive tumors in 17 out of 21microarray studies, and HOXB2 is more
highly expressed in estrogen receptor positive cell lines compared to
more aggressive, estrogen negative cell lines [29]. HOXB2 was
signiﬁcantly underexpressed in higher grade tumors: using Oncomine
to perform a Grade Analysis for HOXB2 in breast cancer, HOXB2
expression was signiﬁcantly lower (pb .05) in Grade 3 tumors in 7 out
of the 14 microarray studies present (pb .00001[27]). Our observa-
tions that reducing HOXB2 expression increases mitosis ﬁgures and
tumor growth in vivo are consistent with the observed effects on
grade and outcome.
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tumor screen compared to the experimental lung metastasis screen.
This may indicate the importance of paracrine interactions between
cells in the tumor microenvironment, where cells interact closely in a
mixed population, compared to tail vein injection where individual
clones may seed in the lung and grow out in relative isolation.
Paracrine signaling between cells could provide a selective pressure in
the developing tumor, and an exciting outcome of this screen is the
possibility of identifying genes needed for competition within the
developing tumor cell population but which do not alter tumor
growth in a clonal population. Previous studies have explored the
evolving heterogeneity in the tumor microenvironment [30,31]. We
have identiﬁed the CYBA gene as a gene that may provide a selective
advantage in the heterogeneous, developing tumor microenviron-
ment. Although the CYBA knockdown line on its own showed normal
growth rates, when present in either the original pool or in varied
mixtures (Supplemental Fig. 5), with the control line, its representa-
tion was signiﬁcantly reduced. The concept of genes which are
correlated with prognosis and alter the ability of a proportion of cells
expressing this gene at a particular level to competewith other cells in
the tumor microenvironment is novel and could be elaborated on
using the methods we describe.
Our studies also indicate limitation of this approach given current
technology. Many of the shRNA vectors did not provide efﬁcient
knockdown of our target genes, and it was often a challenge to ﬁnd at
least one knockdown above 50% to use in the screen. Another
unexpected result was our ﬁnding that the shRNA advertised as being
a non-targeting control (CT1) increased almost 10 fold after tumor
growth in the screen, and this result was validated evaluating the
individual cell line. This indicates that this non-targeting shRNA most
likely had an off target effect, since other cell lines such as SERPINE1-A
and TGBI-C grew similarly to the parental cell line and each other
(Table 2). Thus further improvements in the selection of knockdown
sequences and development of vectors for suppression would be
valuable. In addition, although we noted that lines with reduced
expression of potential positive effectors ID1, VCAM1, EREG, and
IL13RA2 decreased in proportion during primary tumor growth,
correlating with previous studies [32,33], we did not see a signiﬁcant
decrease in these lines or lines with reduced expression of EGFR or
RHOC in the experimental lung metastasis screen. This is inconsistent
with previous work showing VCAM1, IL13RA2, and ID1 were
important for lung metastasis [11,32,33]. There are several possible
explanations for this difference. These discrepancies may be due to:
1) lower knockdown efﬁciencies in some cases (ID-1 and EGFR),
2) differences in the MDA-MB-231 subline used, (clone 4173 in our
study vs. the 4175 clone previously characterized), or 3) different
methods used to measure metastasis (histology in our study vs.
bioluminescence). While RHOC has been shown to be important for
metastasis in breast cancer [34,35], it has not been previously
characterized as necessary for MDA-MB-231 in vivo metastasis or
speciﬁcally shown to affect the metastatic ability of the 4173 clone.
In summary, our studies demonstrate the value of using in vivo
approaches to identify genes whose contributions to breast cancer
malignancy may be difﬁcult to identify in vitro. Our data indicate that
the tumor microenvironment, as determined both by the different
types of stromal cells present as well as the heterogeneity of the
tumor cell population that evolves during tumor progression, plays a
role in selecting for the expression of genes which are then correlated
with patient outcome.
4. Materials and methods
4.1. Tissue culture
The parental MDA-MB-231 cells were derived from the pleural
effusion of a breast cancer patient [36]. Clone 4173, kindly provided byJoan Massague, was identiﬁed as being highly metastatic, speciﬁcally
to the lungs, after in vivo selection of parental MDA-MB-231 cells for
lungmetastasis [11]. All the studies withMDA-MB-231 cells described
in this paper were performed with the 4173 clone. MDA-MB-231 cell
lines were cultured in DMEM (Cellgro, Manassas, VA), 10% fetal
bovine serum, FBS (S11550 Atlanta Biologicals, Lawrenceville, GA),
and penicillin (100 units/ml)-streptomycin (0.1 mg/ml). MTLn3-
ErbB1 rat adenocarcinoma cells expressing ErbB1 [12] were cultured
in alpha MEM, 5% FBS. All cell lines were cultured at 37 °C and 5% CO2.
To generate the individual shRNA transductant cell lines, pGipz shRNA
GFP lentiviral vectors (Supplemental Table 1, Open Biosystems,
Huntsville, AL) were transfected into HEK 293T/17 cells (American
Type Culture Collection) with packaging vectors TAT, REV, GAG/POL
and VSV-G using Fugene 6 Transfection Reagent (11 815 091 001,
Roche, Indianapolis, IN). Tumor cells were transduced with superna-
tants containing virus in the presence of polybrene (8 μg/ml) and
placed under puromycin selection (1 μg/ml) for 2 weeks. The JP1520
empty control vector and HOXB2 cDNA retroviral vectors were
obtained from the Dana-Farber/Harvard Cancer Center DNA Resource
Core and were transfected into Phoenix cells (kindly provided by
Dr. Gary P. Nolan) using Fugene 6. The supernatant was used to
transduce tumor cells with polybrene (8 μg/ml) and selected for
puromycin resistance as above. To make the pooled population the
twenty ﬁve individual shRNA cell lines were counted and combined in
equal proportions in groups of 5. The ﬁve groups were then combined
into one large pool and grown to 80% conﬂuence on 15 cm dishes for
isolation of gDNA from the initial pool, in vivo injections, in vitro
growth, and storage of stocks.
For in vitro growth, the initial pool was split 1:5, 3 times per week
in the absence of puromycin. These cultures were placed under
puromycin selection after 4 and 6 weeks of in vitro growth in parallel
to the isolation and plating of in vivo samples in puromycin. gDNAwas
isolated at 4 weeks (corresponding to the times for experimental lung
metastasis analyses using tail vein injection), and 6 weeks (corre-
sponding to orthotopic primary tumor growth and spontaneous
metastasis using mammary fat pad injection).
4.2. RNA extraction, PCR ampliﬁcation, and real-time PCR to evaluate
gene expression
To evaluate gene expression in the individual cell lines (Supplemental
Table 1), RNA was isolated from ~70% conﬂuent 10 cm dishes using the
RNeasy mini kit, (74104, Qiagen, Valencia, CA). DNA was digested with
RNase free DNase (79254, Qiagen, Valencia, CA). One microgram of total
RNA was reverse transcribed into cDNA using the Superscript III ﬁrst
strand synthesis kit, (11752-050, Invitrogen, Carlsbad, CA). 100 ng of
cDNA was evaluated with SABiosciences qRT-PCR Primer Assay sets for
each gene (Supplemental Table 2). qRT-PCR was performed in triplicate
using SYBR greenmastermix (PA-012, SAbiosciences, Frederick,MD) and
a two-step cycling program (supplemental materials and methods), for
the Applied Biosystems 7900HT. Results were evaluated with ABI Prism
SDS 2.1 software, and themean threshold cycle (CT) values were used for
analysis. To determine the expression levels of each gene the average CT
was compared to theGAPDHhousekeepinggene (SAbiosciences, qRT-PCR
Primer Assay PPH00150E).
4.3. Animal models
All procedures involving mice were conducted in accordance with
the National Institutes of Health regulations concerning the use and
care of experimental animals and were approved by the Albert
Einstein College of Medicine animal use committee. The pool of shRNA
transductants, or MDA-MB-231 individual shRNA cell lines (for
growth evaluation) was grown to 80% conﬂuence and detached
with PBS containing 2 mM EDTA. One million cells in PBS, .7% Bovine
Serum Albumin (w/v), BSA, and 20% (v/v) type I collagen (354249,
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fourth mammary fat pad from the head of 5 to 7 week old female
severe combined immunodeﬁcient (SCID) mice (National Cancer
Institute, Frederick, MD). MTLn3 ErbB1 JP1520 and MTLn3 ErbB1
HOXB2 ORF cell lines were detached in PBS, 2 mM EDTA and 1×106
cells resuspended in PBS, 0.35% BSA for injection into the mammary
fat pads of 5 female SCID mice per line to evaluate growth. Injections
of the pool were done at two separate times with 5 mice and then 4
mice to account for any injection differences. After six weeks of
growth, when tumors reached 1.5 to 2 cm in diameter, they were
removed for evaluation of transductant proportions in the screen.
For in vivo primary tumor growth analysis of individual cell lines,
tumor growth ratewasmonitored at weekly intervals bymeasuring in
two dimensions, and tumor volumes were calculated using the
formula: length×width2/2. Tumors were measured every 3 days
starting from day 18 post injection, for up to 58 days. After growth
analysis tumors were ﬁxed in 10% neutral formalin buffer, embedded
in parafﬁn, sectioned at 5 μm and stained by H&E. Mitotic ﬁgures were
counted in each ﬁeld using a 20× objective in tumor sections taken
from samples grown for 6 weeks. Mitotic ﬁgures were counted for 5
tumors per line in 10 random ﬁelds of healthy tumor parenchyma.
Total numbers of cells were counted per ﬁeld and the percentage of
cells in mitosis was calculated as the number of cells in mitosis/the
total number of cells×100.
To evaluate growth and seeding in lung metastases, the pool of
shRNA transductants was detached with PBS 2 mM EDTA and 1×106
cells in PBS (-Ca/-Mg) were injected into the lateral tail vein of female
SCID mice. After 4 weeks the lungs were removed for evaluation of
lung metastasis. The degree of lung metastasis was evaluated
immediately after dissection using a ﬂuorescence dissecting micro-
scope to evaluate surface GFP ﬂuorescent lung metastases. Lungs
containing at least 1000metastases were used for further analysis. For
individual cell line evaluation of lung seeding and growth 2.5×105
cells were injected into the tail veins of SCID mice and after 3 weeks
lungs were ﬁxed in 10% neutral formalin buffer, embedded in parafﬁn,
sectioned at 5 μm and stained by H&E. For each lung sample,
metastases were counted using a 20× objective.
4.4. Genomic DNA isolation, and qRT-PCR analysis to evaluate pool
proportions
Lungs and primary tumors were chopped into small pieces,
washed in PBS, and dissociated in PBS with collagenase type IV
(6 mg/ml, C5138, Sigma, St. Louis, MO), hyaluronidase (1 mg/ml,
H3506 Sigma), and DNase I (0.25 mg/ml, D5025-15KU, Sigma) for
30 min with continuous agitation at 37 °C. Following digestion,
samples were washed twice in sterile PBS. A minimum of at least
100,000 resistant cells grew out from the in vivo samples cultured
under puromycin selection. gDNA was isolated from samples for
subsequent analysis after no longer than one week in culture when
100 mm dishes were about 70% conﬂuent (DNeasy kit 69504, Qiagen,
Valencia, CA). The in vitro injected pool was cultured in parallel during
the in vivo growth steps without puromycin selection and then was
also grown under puromycin selection in parallel with the cells
isolated from the in vivo samples.
Unique barcode sequences for each of the pGipz shRNA vectors
were sequenced using the sequencing primer GCATTAAAGCAGCG-
TATC. To analyze changes in the proportions of individual trans-
ductants after growth in vivo, qRT-PCR barcode reverse primers were
designed with Primer 3 software, speciﬁc to each individual barcode
(Supplemental Table 3) [8]. A common forward primer was used
(Supplemental Table 3). Primers were designed based on qRT-PCR
primer parameters and tested with qRT-PCR of the individual cell
line's gDNA, prior to their use in the screen. Speciﬁc barcode primers
were aligned using the EMBOSS Pairwise Alignment Algorithm [37],
with other cell line barcodes and sequences. Primers with alignmentscores above 60% similarity to other barcodes were evaluated for
mispriming to test the speciﬁcity of each of the primer sets. 100 ng of
total gDNA and 500 nM of primers (common forward and speciﬁc
barcode reverse primer), were used for each triplicate reaction. For
each gDNA sample, the level of the endogenous beta actin gene was
used to normalize to total genomic DNA (Suppl. Table 3), by
subtracting the beta actin CT from the barcode CT, producing a ΔCT
using the average CT of the triplicate reactions. The change in
representation of each barcode between two samples was calculated
as a ΔΔCT: the difference between the ΔCT's for that barcode of the
two populations being compared. The CT values for all transductants
in the in vivo and in vitro samples were measured at least twice on
different days done in triplicate for each qRT-PCR reaction.
4.5. Selection of genes for screening
To evaluate which genes to use in the screen, three microarray
studies, correlating gene expressionwith patient survival, were used for
analysis [2,4,5]. p Values were generated in a t-test comparing the
median difference in expression of a particular gene between patients
survivingN5 years vs.b5 years in each study. Themedian of the p values
for a particular gene across all three microarray studies was used to
generate a list of genes whose expression is correlated positively
(potential tumor growth or metastasis suppressor), or negatively
(potential tumor growth or metastasis enhancer) with survival. The
top twenty ﬁve genes (with the lowest median p value) were selected
for development of an in vivometastasis screen, (Supplemental Table 1).
Their correlation with survival was also conﬁrmed in the Oncomine
microarray database. Utilizing the data in [29], the average level of
expression of the selected genes in MDA-MB-231 cells is similar to the
other breast cancer cell lines (mean and SEM of the ratio 1.02+/− .03).
Potential positive controls in the screen were genes (ID1, IL13RA2, and
VCAM1, EREG, EGFR) shown previously to be mediators of growth or
metastasis and correlated with poor prognosis [11,12,33]. A non-
targeting shRNA from Openbiosystems, CT-1, was used as a negative
control.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2011.05.011.
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